Baker Bros. Advisors 13F: New $24M Stake in GENB

Baker Bros. Advisors Enters Generate Biomedicines

Prominent healthcare investment firm Baker Bros. Advisors established a brand-new position in Generate Biomedicines, Inc. (NASDAQ: GENB) during the first quarter. According to its latest Form 13F filing with the Securities and Exchange Commission, the fund acquired 1,423,602 shares of the biotechnology company. The newly formed stake was valued at approximately $24.0 million at the end of the reporting period.

The investment firm paid an estimated average cost basis of $12.66 per share to build its position. Because 13F filings are backward-looking and represent holdings as of March 31, 2026, the fund's current positioning may have changed since the period ended.

Stock Trends Upward Since Fund Purchases

Generate Biomedicines shares closed at $16.87 on Sunday, showing strong upward momentum compared to the estimated $12.66 entry price paid by Baker Bros. Advisors. The stock is currently trading above both its 50-day moving average of $15.22 and its 200-day moving average of $14.08.

Over the past year, the biotechnology stock has traded as low as $11.00 and as high as $22.67. With a current ratio of 8.30 and a quick ratio of 8.08, the company maintains a highly liquid balance sheet, which is common for clinical-stage drug developers managing high research expenses.

Recent Earnings

In its most recent financial reports, Generate Biomedicines disclosed annual revenue of $26.48 million, which represents a revenue decline of 37.7%. The company is not yet profitable, posting a net loss that resulted in earnings per share (EPS) of -$2.09. Because the firm does not have positive earnings, it does not have a meaningful price-to-earnings (P/E) ratio. Investors looking for the next financial update can watch for the company's next earnings report, which is scheduled for November 5, 2026.

Analysts Set New Price Targets

Wall Street analysts have taken a very positive view of the biotechnology company. On October 5, 2026, H.C. Wainwright reiterated its Buy rating on the stock with a $30.00 price target. The firm previously reiterated that same $30.00 target on September 8, 2026, after lifting it from $25.00 on August 28, 2026.

Among the five analysts covering the stock, the consensus recommendation is a strong buy. The average price target for the stock stands at $27.00, with estimates ranging from a low of $22.00 to a high of $30.00.

Programming Protein Therapeutics

Generate Biomedicines uses machine learning and artificial intelligence to design and program novel protein therapeutics. Rather than relying on traditional drug discovery, the company's proprietary platform aims to engineer specific proteins to target diseases. Its pipeline includes GB-0895, a long-acting antibody being developed to treat severe asthma with twice-yearly dosing, as well as therapies targeting oncology and other immunological conditions.

What's Ahead for Generate Biomedicines, Inc.

Market observers will likely monitor whether Baker Bros. Advisors continues to build on this new biotechnology stake in subsequent quarters. Investors should keep in mind that 13F filings are disclosed up to 45 days after the end of the calendar quarter and do not reflect real-time trading decisions, nor do they constitute a recommendation to buy or sell the stock.